news & events
WALTHAM, MA – January 15, 2015 – Sevo Nutraceuticals, Inc. announced today that PERCEPTIV ® Phase II clinical trial results were published this month in the online version of the Journal of Alzheimer’s Disease1 . PERCEPTIV is its clinically proven, cognitive health supplement available to the public without a prescription.
UMASS Lowell professor Dr. Thomas Shea and his research team completed a Phase II Clinical Trial, in which more than 100 individuals diagnosed with Alzheimer’s disease, received either the PERCEPTIV formulation or a placebo (without knowing which one they received). After three months, those receiving PERCEPTIV demonstrated improved cognitive performance, memory, and mood while those receiving the placebo did not improve. Individuals on the placebo were then switched to the PERCEPTIV formulation. These and all other participants continued to improve over the course of one year, with no serious adverse events. The results, critically reviewed and approved by experts in the field, were just published in the online version of the Journal of Alzheimer’s Disease, and will appear in the Journal’s print edition in March 2015.
These studies, referred to as “phase II,” were funded by a grant to Dr. Shea from the Alzheimer’s Association, and confirm earlier “phase I” studies, in which PERCEPTIV™ also improved memory and cognitive performance for 93 individuals with no known or suspected memory difficulties, as well as for other individuals diagnosed with Alzheimer’s disease. Copies of these peer-reviewed studies, published in scientific journals, can be accessed free of charge at www.perceptiv.com.
The PERCEPTIV formulation was licensed from the University of Massachusetts Lowell by Sevo Nutraceuticals in 2012. Importantly, all of Dr. Shea’s studies were completed prior to licensing and there was no corporate involvement in these clinical studies. This is not the case for many nutraceutical products, in which clinical studies are conducted by, or sponsored by, their companies, and which therefore may have an inherent bias and conflict of interest. Additionally, many competing products cite research studies on individual ingredients rather than their formulations as a whole, which does not allow for an accurate assessment of efficacy.
PERCEPTIV addresses one of the most significant issues of well-being facing the United States – cognitive health. The cost of addressing this issue in America is soon expected to top $1 trillion a year. Cognitive health impacts the largest demographic in America, the Baby Boomers, who number 74 million according to US Census data. Based on a report by the National Council on Aging, Americans are twice as fearful of losing mental capacity as having diminished physical ability and 60% of adults are very or somewhat worried about memory loss. These factors point to a growing need for readily available brain health products that are both safe and effective.
PERCEPTIV is patented and the claims of the patent protect the use of the unique formulation of PERCEPTIV in the large and growing segment of brain health and cognitive performance supplements.
The unique formulation found in PERCEPTIV consisting of Vitamin E, Folic Acid, Vitamin B12 and a proprietary blend of N-Acetyl Cysteine, Acetyl L-Carnitine and S-Adenosyl Methionine (SAMe), has been shown to protect against normal cognitive decline associated with aging, improve list recall by over 100%, restore a healthy mood and help increase focus and concentration.*
PERCEPTIV is available from hundreds of resellers in the United States as well as directly at www.perceptiv.com.